Clinical Trials Sponsored by Pharmexa-Epimmune

Total 6899 results

Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/22 Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Recruiting

Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas

Sarcoma | Ewing Sarcoma | Osteoid Sarcoma

China
Shenzhen Geno-Immune Medical Institute

Enrolling by invitation

Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme

Glioblastoma Multiforme | Glioblastoma Multiforme of Brain

China
Immune Response BioPharma, Inc.
cro

Unknown

A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

Multiple Sclerosis

United States
Shenzhen Geno-Immune Medical Institute

Unknown

Engineered Immune Effectors Against Ovarian Cancer

Ovarian Cancer

China
Shenzhen Geno-Immune Medical Institute

Unknown

Gene Transfer for SCID-X1 Using a Self-inactivating Lentiviral Vector （TYF-IL-2Rg）

SCID, X Linked

China
Shenzhen Geno-Immune Medical Institute

Unknown

Lentiviral Gene Therapy for CGD

Chronic Granulomatous Disease

China
Shenzhen Geno-Immune Medical Institute

Unknown

HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of HPV

Human Papilloma Virus

China
Shenzhen Geno-Immune Medical Institute

Unknown

A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies

B-cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Unknown

FANCA Gene Transfer for Fanconi Anemia Using a High-safety, High-efficiency, Self-inactivating Lentiviral Vector

Fanconi Anemia

China
Shenzhen Geno-Immune Medical Institute

Unknown

Immunotherapy Treating GI Cancer

Cancer

China
Shenzhen Geno-Immune Medical Institute

Withdrawn

Intervention of Engineered Immune Effector T Cells Against Lung Cancer

NSCLC | Lung Cancer

China
Shenzhen Geno-Immune Medical Institute

Unknown

Study on GD2 Positive Solid Tumors by 4SCAR-GD2

Solid Tumor

China
Shenzhen Geno-Immune Medical Institute

Recruiting

Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells

Autoimmune Diseases

China
Boston Immune Technologies and Therapeutics

Not yet recruiting

A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System

Peripheral T-cell Lymphoma | NHL | Cutaneous T Cell Lymphoma
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/79b Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/70 Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Recruiting

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

Acute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell Lymphoma

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CAR-T Immunotherapy Targeting CD19- ALL

B-cell Leukemia

China
Immune Response BioPharma, Inc.
cro

Recruiting

A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

Multiple Sclerosis | Secondary Progress Multiple Sclerosis

United States
Cargill
Natural Immune Systems Inc

Completed

EpiCor Clinical Study on Rapid Immune Modulating Effects

Immune Surveillance

United States
Shenzhen Geno-Immune Medical Institute

Unknown

Genetically Modified T Cells Against Ovarian Cancer

Ovarian Cancer

China
Shenzhen Geno-Immune Medical Institute

Unknown

Intervention of Bladder Cancer by CAR-T

Bladder Cancer | Urothelial Carcinoma Bladder

China
Shenzhen Geno-Immune Medical Institute

Unknown

Lentiviral Gene Therapy for X-ALD

X-linked Adrenoleukodystrophy

China
Shenzhen Geno-Immune Medical Institute

Unknown

Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections

Tuberculosis | CMV Infection | EBV Infection | Adenovirus Infection | Fungus Infection | Pathogen Infection | BKV Infection

China
Shenzhen Geno-Immune Medical Institute

Unknown

Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

Multiple Myeloma

China
Shenzhen Geno-Immune Medical Institute

Unknown

Lentiviral FIX Gene Therapy

Hemophilia B
Shenzhen Geno-Immune Medical Institute

Unknown

Lentiviral FVIII Gene Therapy

Hemophilia A

China
Shenzhen Geno-Immune Medical Institute

Suspended

Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors

Ovarian Cancer

China
Tufts Medical Center
Immune Control

Completed

Fluphenazine Hydrochloride for Psoriasis (FP-CL2)

Psoriasis

United States
Memorial Sloan Kettering Cancer Center
MedImmune LLC

Completed

Brain Irradiation and Tremelimumab in Metastatic Breast Cancer

Metastatic Breast Cancer

United States
M.D. Anderson Cancer Center
AstraZeneca; MedImmune LLC

Withdrawn

MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)

Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma | Advanced Lung Cancer | Recurrent Nonsmall Cell Lung Cancer
MedImmune LLC
University of Pittsburgh; Passport Health

Completed

Assessing Choice in the Employer Setting (ACES) Study (MA181)

Healthy

United States
Mt. Sinai Medical Center, Miami
MedImmune LLC

Completed

Subcutaneous Amifostine Safety Study

Lymphoma | Head and Neck Cancer | Lung Cancer

United States
Shenzhen Geno-Immune Medical Institute

Recruiting

GD2/CD56 Bi-specific CAR-T Cell Therapy

Malignant Disease

China
Shenzhen Geno-Immune Medical Institute

Recruiting

PSMA/CD70 Bi-specific CAR-T Cell Therapy

Cancer Disease

China
Shenzhen Geno-Immune Medical Institute

Recruiting

NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL

T-Cell Acute Lymphoblastic Leukemia

China
Shenzhen Geno-Immune Medical Institute

Recruiting

NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL

B-Cell Acute Lymphoblastic Leukemia

China
Shenzhen Geno-Immune Medical Institute

Recruiting

Multiple CAR-T Cell Therapy Targeting AML

Acute Myeloid Leukemia

China
Immune-Onc Therapeutics
Regeneron Pharmaceuticals

Completed

First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

Solid Tumor, Adult

United States
Shenzhen Geno-Immune Medical Institute

Unknown

Gene Transfer for ADA-SCID Using an Improved Lentiviral Vector (TYF-ADA)

Adenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID)

China
Shenzhen Geno-Immune Medical Institute

Unknown

Lentiviral Gene Therapy for MLD

Metachromatic Leukodystrophy (MLD)

China
Shenzhen Geno-Immune Medical Institute

Unknown

Engineered Immune Effectors Against Cervical Cancer

Cervical Cancer

China
Shenzhen Geno-Immune Medical Institute

Unknown

Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells

Cancer

China
Shenzhen Geno-Immune Medical Institute

Unknown

Antigen-specific T Cells Against Lung Cancer

Lung Cancer

China
Shenzhen Geno-Immune Medical Institute

Unknown

Intervention of CAR-T Against Cervical Cancer

Cervical Cancer

China
Shenzhen Geno-Immune Medical Institute

Unknown

Combination CAR-T Cell Therapy Targeting Hematological Malignancies

B-cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Unknown

Clonal Fetal Mesenchymal Stem Cells (cfMSCs) for the Control of Immune-related Disorders

Tissue Damage | Immune Related Disorder

China
Shenzhen Geno-Immune Medical Institute

Unknown

Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector

Beta-Thalassemia

China
Tufts Medical Center
Immune Control

Terminated

Fluphenazine Decanoate for Psoriasis

Psoriasis

United States

Clinical Trials Sponsored by Pharmexa-Epimmune

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations